Found: 8
Select item for more details and to access through your institution.
Anlotinib suppresses the DNA damage response by disrupting SETD1A and inducing p53-dependent apoptosis in Transformed Follicular Lymphoma.
- Published in:
- International Journal of Medical Sciences, 2024, v. 21, n. 1, p. 70, doi. 10.7150/ijms.84952
- By:
- Publication type:
- Article
Chidamide and apatinib are therapeutically synergistic in acute myeloid leukemia stem and progenitor cells.
- Published in:
- Experimental Hematology & Oncology, 2022, v. 11, n. 1, p. 1, doi. 10.1186/s40164-022-00282-1
- By:
- Publication type:
- Article
Orelabrutinib and venetoclax synergistically induce cell death in double-hit lymphoma by interfering with the crosstalk between the PI3K/AKT and p38/MAPK signaling.
- Published in:
- Journal of Cancer Research & Clinical Oncology, 2023, v. 149, n. 9, p. 5513, doi. 10.1007/s00432-022-04473-5
- By:
- Publication type:
- Article
Identification of crucial genes of pyrimidine metabolism as biomarkers for gastric cancer prognosis.
- Published in:
- Cancer Cell International, 2021, v. 21, n. 1, p. 1, doi. 10.1186/s12935-021-02385-x
- By:
- Publication type:
- Article
Preclinical Evaluation of the HDAC Inhibitor Chidamide in Transformed Follicular Lymphoma.
- Published in:
- Frontiers in Oncology, 2021, v. 11, p. 1, doi. 10.3389/fonc.2021.780118
- By:
- Publication type:
- Article
Therapeutic Interaction of Apatinib and Chidamide in T-cell Acute Lymphoblastic Leukemia through Interference with Mitochondria Associated Biogenesis and Intrinsic Apoptosis.
- Published in:
- Journal of Personalized Medicine, 2021, v. 11, n. 10, p. 977, doi. 10.3390/jpm11100977
- By:
- Publication type:
- Article
The synergy of the XPO1 inhibitors combined with the BET inhibitor INCB057643 in high-grade B-cell lymphoma via downregulation of MYC expression.
- Published in:
- Scientific Reports, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41598-023-45721-z
- By:
- Publication type:
- Article
Preclinical Studies of Chiauranib Show It Inhibits Transformed Follicular Lymphoma through the VEGFR2/ERK/STAT3 Signaling Pathway.
- Published in:
- Pharmaceuticals (14248247), 2023, v. 16, n. 1, p. 15, doi. 10.3390/ph16010015
- By:
- Publication type:
- Article